Request Demo

Last update 20 Mar 2025

Dual agonist combination therapy (Intarcia Therapeutics)

Last update 20 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Biological products

Synonyms

dual agonist combination 1 therapy (Intarcia Therapeutics), dual agonist combination 2 therapy (Intarcia Therapeutics), dual agonist combination 3 therapy (Intarcia Therapeutics)

Target-

Action-

Mechanism-

Therapeutic Areas

Digestive System DisordersEndocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2Nonalcoholic SteatohepatitisObesity

Inactive Indication-

Originator Organization

Intarcia Therapeutics, Inc.

Active Organization

Intarcia Therapeutics, Inc.

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

100 Clinical Results associated with Dual agonist combination therapy (Intarcia Therapeutics)

100 Translational Medicine associated with Dual agonist combination therapy (Intarcia Therapeutics)

100 Patents (Medical) associated with Dual agonist combination therapy (Intarcia Therapeutics)

Literatures (Medical) associated with Dual agonist combination therapy (Intarcia Therapeutics)

12 Feb 2023·Orvosi Hetilap

A „másik” inkretin – a glükózdependens insulinotrop polipeptid terápiás újrafelfedezése

Review

Author: Schandl, László ; Kis, János Tibor ; Winkler, Gábor

01 Dec 2002·Medical science monitor : international medical journal of experimental and clinical research

Characterization of dendritic cells generated in vivo by an E. coli derived chimeric dual receptor agonist.

Article

Author: Doshi, Parul D ; Yu, Mingfu ; Welply, Joseph K ; McGarity, Kelly L ; Lie, Wen-Rong ; Bono, Christine P ; Rankin, Anne M ; Kahn, Larry E ; Woulfe, Susan L ; Streeter, Philip R ; Smidt, Mary L ; Klein, Barbara K

BACKGROUNDProgenipoietin-4 (ProGP-4) is an E. coli derived chimeric growth factor that activates the human Flt3 and G-CSF receptors. ProGP-4 possesses cross-species activity and treatment of mice with ProGP-4 results in increases in the number of WBC and Class II+/CD11c+ cells in both spleen and peripheral blood. Herein, we report morphologic, phenotypic and functional evaluation of Class II+/CD11c+ cells generated by in vivo administration of ProGP-4.MATERIAL/METHODSC57BL/6 mice were injected daily with ProGP for 7 to 18 days. Leukocytes from spleen and peripheral blood were analyzed by flow cytometry to enumerate and characterize changes in DC populations. Spleens from ProGP treated mice were evaluated by immunocytochemistry and enriched CD11c+ populations were functionally assessed in a mixed lymphocyte assay and in an antigen dependent CTL assay.RESULTSAdministration of this dual receptor agonist to mice resulted in dose-dependent increases in the numbers of total white blood cells and Class II+/CD11c+ cells in spleen and peripheral blood. CD11c+ cells from ProGP-4 treated mice co-expressed DEC205 and also expressed CD80, CD86 and CD40, albeit at lower levels as compared to Class II+/CD11c+ cells from untreated animals. Despite lower co-stimulatory molecule expression, ProGP-4-generated Class II+/CD11c+ cells stimulated proliferation of allogeneic T cells and an antigen-specific T cell hybridoma as efficiently as bone marrow derived dendritic cells from untreated mice.CONCLUSIONSThe data presented in this report highlight the ability of E. coli derived ProGP-4 to expand large numbers of functional DC in the peripheral blood and lymphoid organs in vivo using a rodent model of hematopoiesis. E. coli derived chimeric receptor agonists such as ProGP-4 may enable further investigations of immunotherapeutic approaches to the treatment of diseases such as cancer and autoimmunity.

01 Aug 2001·Experimental HematologyQ4 · MEDICINE

Progenipoietin-1

Q4 · MEDICINE

Article

Author: William H Fleming ; Jean M Mulcahy ; Philip R Streeter ; John P McKearn

OBJECTIVEProgenipoietin-1 is an agonist of both the granulocyte colony-stimulating factor and fetal liver tyrosine kinase-3 receptors capable of inducing the proliferation of multiple hematopoietic cell lineages. The potential of progenipoietin-1 to mobilize transplantable hematopoietic stem cells into the peripheral blood was evaluated.METHODSCohorts of donor mice were treated with either progenipoietin-1, fetal liver tyrosine kinase-3 ligand, granulocyte colony-stimulating factor, or a vehicle control. Hematopoietic progenitor/stem-cell activity in donor blood was assayed by radioprotection, multilineage reconstitution, secondary transplantation, and competitive repopulation.RESULTSOnly 1 microL of peripheral blood from progenipoietin-1-treated donors was required to protect 80% of lethally irradiated mice, while in contrast 1 microL of peripheral blood from granulocyte colony-stimulating factor-treated donors failed to protect any recipients. The radioprotected recipients of progenipoietin-1-treated donor cells showed donor-derived (Ly5.2) multilineage hematopoietic reconstitution for up to 6 months. Serial transplantation studies using bone marrow from radioprotected, chimeric recipients demonstrated long-term donor-derived hematopoiesis, indicating the successful transplantation of multipotent hematopoietic stem cells. The engraftment potential of progenipoietin-1 donor-derived cells was directly compared with donors treated with granulocyte colony-stimulating factor or fetal liver tyrosine kinase-3 ligand alone or in combination. Both spleen colony-forming activity and competitive repopulating activity was highest in the blood from progenipoietin-1-treated donors.CONCLUSIONSThese studies demonstrate that progenipoietin-1 is a potent mobilizer of transplantable hematopoietic stem cells and indicate that this dual-receptor agonist has greater biologic activity than its constituent molecules.

100 Deals associated with Dual agonist combination therapy (Intarcia Therapeutics)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Discovery	United States	Intarcia Therapeutics, Inc.	-
Nonalcoholic Steatohepatitis	Discovery	United States	Intarcia Therapeutics, Inc.	-
Obesity	Discovery	United States	Intarcia Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Dual agonist combination therapy (Intarcia Therapeutics)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation